These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28814193)

  • 1. Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient.
    Engle JA; Fair C
    J Oncol Pharm Pract; 2018 Dec; 24(8):627-631. PubMed ID: 28814193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient.
    Wasko JA; Westholder JS; Jacobson PA
    J Oncol Pharm Pract; 2017 Jan; 23(1):75-79. PubMed ID: 26763003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
    Kieu V; Jhangiani K; Dadwal S; Nakamura R; Pon D
    Transpl Infect Dis; 2019 Feb; 21(1):e13007. PubMed ID: 30295407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation.
    Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S
    Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact and management of fluconazole discontinuation on sirolimus levels in bone marrow transplant patients.
    Nwaroh E; Jupp J; Jadusingh E; Guilcher G
    J Oncol Pharm Pract; 2018 Apr; 24(3):235-238. PubMed ID: 28355970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated red blood cell exchange for acute drug removal in a patient with sirolimus toxicity.
    Galera P; Martin HC; Welch L; Sulmasy P; Cerny J; Greene M; Vauthrin M; Bailey JA; Weinstein R
    J Clin Apher; 2015 Dec; 30(6):367-70. PubMed ID: 25619898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.
    Schleuning M; Judith D; Jedlickova Z; Stübig T; Heshmat M; Baurmann H; Schwerdtfeger R
    Bone Marrow Transplant; 2009 May; 43(9):717-23. PubMed ID: 19011660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury.
    El-Asmar J; Gonzalez R; Bookout R; Mishra A; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2016 Dec; 9(4):157-161. PubMed ID: 26684920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient.
    Nalli N; Stewart-Teixeira L; Dipchand AI
    Pediatr Transplant; 2006 Sep; 10(6):736-9. PubMed ID: 16911499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
    Claxton DF; Ehmann C; Rybka W
    Br J Haematol; 2005 Jul; 130(2):256-64. PubMed ID: 16029454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient.
    Said A; Garnick JJ; Dieterle N; Peres E; Abidi MH; Ibrahim RB
    Pharmacotherapy; 2006 Feb; 26(2):289-95. PubMed ID: 16466336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
    Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
    Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant sirolimus and dronedarone interaction in a kidney transplant recipient.
    Tichy EM; Medwid AJ; Mills EA; Formica RN; Kulkarni S
    Ann Pharmacother; 2010; 44(7-8):1338-41. PubMed ID: 20484171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.
    Groen-Wijnberg M; van Dijk J; Krauwinkel W; Kerbusch V; Meijer J; Tretter R; Zhang W; van Gelderen M
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):417-429. PubMed ID: 27350625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.